Clinical Performance of a Silicone Hydrogel for Daily Disposable Wear
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Longwood, Florida, Forenede Stater, 32779
- Alcon Investigative Site
-
Maitland, Florida, Forenede Stater, 32751
- Alcon Investigative Site
-
-
Georgia
-
Johns Creek, Georgia, Forenede Stater, 30097
- Alcon Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Able to understand and sign an IRB-approved Informed Consent Form;
- Successful wear of spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months:
- Manifest cylinder of ≤ 0.75 diopter (D) in each eye;
- Best corrected visual acuity (BCVA) of 20/25 or better in each eye;
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Any anterior segment infection, inflammation, abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the Investigator;
- Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the Investigator;
- History of refractive surgery or plan to have refractive surgery during the study;
- Ocular or intraocular surgery within the previous 12 months or planned during the study;
- Current or history of pathologically dry eye in either eye that, in the opinion of the Investigator, would preclude contact lens wear;
- Any previous or current wear of MYDAY;
- Habitually wearing monovision or multifocal lenses during the last 3 months;
- Routinely sleeping in lenses for at least 1 night per week over the last 3 months prior to enrollment;
- Any use of topical ocular medications and artificial tear or rewetting drops that would require instillation during contact lens wear;
- Other protocol-defined exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Andet: FID122819, then stenfilcon A
FID122819 contact lenses worn first, followed by stenfilcon A contact lenses, as randomized.
Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
|
Investigational spherical silicone hydrogel contact lenses for daily disposable wear
Andre navne:
Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Andre navne:
|
|
Andet: Stenfilcon A, then FID122819
Stenfilcon A contact lenses worn first, followed by FID122819 contact lenses, as randomized.
Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
|
Investigational spherical silicone hydrogel contact lenses for daily disposable wear
Andre navne:
Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Visual Acuity (VA)
Tidsramme: Baseline/Dispense (Day 1), Week 1, each product
|
VA was assessed and collected using a Snellen chart.
Conversion to logMAR (logarithm of the minimum angle of resolution) was performed.
A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.
Both eyes contributed to the analysis.
|
Baseline/Dispense (Day 1), Week 1, each product
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Sr. Clinical Manager, Trial Management Operations, Alcon, A Novartis Division
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CLE383-C003
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .